Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences

Abbott’s $23B Bet on Exact Sciences: Bold Move or Risky Gamble?

Abbott’s $23 billion acquisition of Exact Sciences positions the company to become a major player in cancer diagnostics. Experts think the deal makes strategic sense, as it offers higher margins and a broader commercial scale — but questions remain about long-term growth amid rising competition and the challenges of integrating a patient-focused, tech-heavy business. The post Abbott’s $23B Bet on Exact Sciences: Bold Move or Risky Gamble? appear…

Abbott to acquire Exact Sciences in $21 billion deal, aiming to lead in fast-growing cancer diagnostics market

Deal is expected to accelerate innovation in cancer diagnostics and expand access to early detection tools at a time when global cancer rates continue to climb

Abbott Breaks into Lucrative Cancer Screening Market with $21 Billion Exact Sciences Purchase

Suburban Chicago is a long way from Britain, but they’re still calling it a bloody good deal. Illinois-based healthcare giant Abbott Laboratories said Thursday that it agreed to buy cancer-screening specialist Exact Sciences and its breakthrough blood test for $21 billion. Match Made in Lab Heaven Founded in 1880s Chicago by a pharmacist with a talent for formulating medicines from plants and herbs, Abbott is now a multinational healthcare giant…

Abbott to acquire Madison-based Exact Sciences for $23 billion

MADISON, Wis. — Abbott agrees to acquire Exact Sciences for an estimated value up to $23 billion. The acquisition will include Exact Sciences’ cancer screening product lines Cologuard®, Oncotype DX®, and Cancerguard™, and possibly the absorption of Exact Sciences’ estimated $1.8 billion of net debt. The Madison-based Exact Sciences focuses on the early detection of cancer and personalized treatments through cancer screening, precision oncology a…

Abbott Labs to acquire Madison’s Exact Sciences in $23 billion deal

The company will maintain its presence in Madison and CEO Kevin Conroy will remain “in an advisory role,” said Zach Brandon, president of the Greater Madison Chamber of Commerce.

Abbott Labs to acquire Madison’s Exact Sciences in $23 billion deal

The company will maintain its presence in Madison and CEO Kevin Conroy will remain “in an advisory role,” said Zach Brandon, president of the Greater Madison Chamber of Commerce.